A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive Italian women

Annals of Oncology

Volumn 25, Issue 1, 2014, Pages 57-63

  Cortesi, L ^a   Razzaboni, E ^a   Toss, A ^a   De Matteis, E ^a   Marchi, I ^a   Medici, V ^a   Tazzioli, G ^a   Andreotti, A ^a   De Santis, G ^a   Pignatti, M ^a   Federico, M ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Acceptability; BRCA1 2 mutation carriers; Genetic counselling; Risk reducing mastectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL EVALUATION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC SCREENING; HETEROZYGOTE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MASTECTOMY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; RISK REDUCTION; TUMOR SUPPRESSOR GENE; WOMEN'S HEALTH;

ACCEPTABILITY; BRCA1/2 MUTATION CARRIERS; GENETIC COUNSELLING; RISK-REDUCING MASTECTOMY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC TESTING; HUMANS; ITALY; MASTECTOMY; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901997020     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt422     Document Type: Article

References (19)

1. Vasen HF, Tesfay E, Boonstra H et al. Early detection of breast and ovarian cancer in families with BRCA mutations. Eur J Cancer 2005; 41: 549-554.
2. Evans DG, Lalloo F, Hopwood P et al. Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. Eur J Surg Oncol 2005; 31: 1112-1118.
3. Evans DG, Shenton A, Woodward E et al. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 2008; 8:155.
4. Graeser MK, Engel C, Rhiem K et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009; 27: 5887-5892.
5. van Sprundel TC, Schmidt MK, Rookus MA et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 2005; 93: 287-292.
6. Schwartz MD, Lerman C, Brogan B et al. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev 2005; 14: 1003-1007.
7. Schlich-Bakker KJ, ten Kroode HF, Ausems MG. A literature review of the psychological impact of genetic testing on breast cancer patients. Patient Educ Couns 2006; 62: 13-20.
8. Schlich-Bakker KJ, Ausems MG, Schipper M et al. BRCA1/2 mutation testing in breast cancer patients: a prospective study of the long-term psychological impact of approach during adjuvant radiotherapy. Breast Cancer Res Treat 2008; 109: 507-514.
9. Wevers MR, Hahn DE, Verhoef S et al. Breast cancer genetic counseling after diagnosis but before treatment: a pilot study on treatment consequences and psychological impact. Patient Educ Couns 2012; 89: 89-95.
10. Frost MH, Slezak JM, Tran NV et al. Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol 2005; 23: 7849-7856.
11. Contegiacomo A, Pensabene M, Capuano I et al. An oncologist-based model of cancer genetic counselling for hereditary breast and ovarian cancer. Ann Oncol 2004; 15: 726-732.
12. Cortesi L, Turchetti D, Marchi I et al. Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience. BMC Cancer 2006; 6: 210.
13. Smith J, Osborn M. Qualitative Health Psychology: Theories and Methods. London: Sage 1999.
14. Van Riel E, Warlam-Rodenhuis CC, Verhoef S et al. BRCA testing of breast cancer patients: medical specialists' referral patterns, knowledge and attitudes to genetic testing. Eur J Cancer Care (Engl) 2010; 19: 369-376.
15. Reavey P, McCarthy CM. Update on breast reconstruction in breast cancer. Curr Opin Obstet Gynecol 2008; 20: 61-67.
16. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
17. Metcalfe KA, Lubinski J, Ghadirian P et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 2008; 26: 1093-1097.
18. Malone KE, Begg CB, Haile RW et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol 2010; 28: 2404-2410.
19. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 2010; 28(2): 222-231.